Evidence map›Paper›PMID 39277293›Full record

ReviewGastrointestinal endoscopy clinics of North America2024

Weight Loss Pharmacotherapy: Current and Future Therapies.

Gabriela Jordan, Sigrid Young, José O Alemán

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastrointestinal endoscopy clinics of North America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gabriela JordanDepartment of Medicine, Margaret Corbin Campus of the VA New York Harbor Health Care System, New York, NY, USA; Laboratory of Translational Obesity Research, NYU Langone Health, New York, NY, USA.
Sigrid YoungDepartment of Medicine, Margaret Corbin Campus of the VA New York Harbor Health Care System, New York, NY, USA; Laboratory of Translational Obesity Research, NYU Langone Health, New York, NY, USA.
José O AlemánDepartment of Medicine, Margaret Corbin Campus of the VA New York Harbor Health Care System, New York, NY, USA; Laboratory of Translational Obesity Research, NYU Langone Health, New York, NY, USA; Holman Division of Endocrinology, New York University Langone Health, 423 East 23rd Street, Room 16-048W, New York, NY 10010, USA. Electronic address: jose.aleman@nyulangone.org.

Funding

Novel regulatory mechanisms controlling hepatic apoB-Lp lipid loading and secretionP01HL160470 · NEW YORK UNIVERSITY D/B/A NYU LONG ISLAND SCHOOL OF MEDICINE · 2025 to 2025
$2.5M
Chylomicrons and endothelial biologyR01HL160891 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2024 to 2025
$1.6M
NHLBI NIH HHS P01 HL160470NHLBI NIH HHS R01 HL160891NIDDK NIH HHS K08 DK117064NIDDK NIH HHS L30 DK126094
6 · The paper itself

Abstract

The rising prevalence of obesity is of major concern. There are currently 5 Food and Drug Administration-approved medications for the treatment of obesity: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide 3.0 mg, and semaglutide 2.4 mg. Surgical options such as bariatric surgery and endoscopic surgery induce more durable weight loss than pharmacotherapy or lifestyle interventions alone. However, patients often experience weight regain and weight loss plateau after surgery. The addition of multimodal or multihormonal pharmacotherapy is a promising tool to address these challenges. The optimal timing of obesity pharmacotherapy with surgical and endoscopic interventions requires further investigation.

Indexed as

Anti-Obesity AgentsNaltrexoneObesityWeight LossBariatric SurgeryBupropionGlucagon-Like PeptidesHumansLiraglutideOrlistatPhentermineSemaglutideTopiramateAnti-Obesity AgentsBupropionGlucagon-Like PeptidesLiraglutideNaltrexoneOrlistatPhentermineSemaglutideTopiramateBariatric surgeryEndoscopic bariatric surgeryGLP-1 agonistObesityPharmacotherapyWeight loss

Identifiers

PMID39277293
PMCPMC11407733

What Socratic holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.